DUBLIN – Lysogene SA is the first European biotech to dip its toes in the IPO waters in 2017, with plans to raise up to €39.7 million (US$42.7 million) on the Euronext exchange in Paris. The Neuilly-sur-Seine, France-based gene therapy firm issued an indicative price range of €6.80 to €9.20 per share Wednesday and plans to price the offer on Feb. 7.